Dr. István Peták is a Dénes Gábor Award-winning physician, cancer researcher, molecular pharmacologist, who has been working in precision oncology, the personalized application of molecularly targeted anti-tumor drugs, for 30 years. Author of more than 200 scientific publications. He is the founder and scientific director of Genomate Health (Boston, USA), founder of Oncompass Medicine, visiting professor at the University of Illinois at Chicago (Chicago, USA), research professor at Széchenyi István University, and senior research fellow at Semmelweis University.
In recent decades, he and his colleagues were the first to apply various methods of molecular diagnostics in the predictive diagnosis of drugs. Now, he and his colleagues have developed the first artificial intelligence-based medical software that can help select molecularly personalized targeted anti-cancer treatments. Their results have been recognized by international professional organizations such as the American Society of Clinical Oncology (ASCO) (Breakthrough Innovations in Oncology Conference Award) and DIGITALEUROPE (Future Unicorn Award), which brings together European technology companies. The Hungarian development was called the next medical breakthrough by the President of the European Commission, Ursula von der Leyen. In 2024, the technology successfully completed the Mayo Clinic (USA) artificial intelligence accelerator program and was accepted into the INVIDIA inception program.
Dr. István Peták has been a member of the American Association for Cancer Research for 27 years. Dr. István Peták represented Hungary in the MIT Regional Entrepreneurship Acceleration Program (REAP). In Hungary, the technology won the Tibor Gyúros Innovation Award from the Hungarian Association of IT Companies (IVSZ) and the IT Innovation Award from the Hungarian Innovation Association.
Dr. István Peták is currently a member of the Executive Council of DIGITALEUROPE.